GlassScriptPhysician profile
Daniel K Hwang
NPI 1629150081
$5,667.08
in general payments reported to CMS, 2019-2025
26 companies · $1,136 in 2025
The $1,136 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,040 · 2020: $385 · 2021: $324 · 2022: $534 · 2023: $938 · 2024: $1,310 · 2025: $1,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,383.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $878.85 | 2019-2025 | Lokelma, Farxiga |
| Akebia Therapeutics INC | $619.80 | 2019-2025 | Auryxia, Vafseo |
| Opko Pharmaceuticals, LLC | $562.23 | 2019-2022 | |
| Vifor Pharma, INC. | $501.37 | 2019-2025 | Veltassa, Korsuva |
| Ardelyx, INC. | $437.64 | 2024-2025 | Ibsrela |
| Amgen INC. | $396.61 | 2019-2024 | Parsabiv, Tavneos, Aranesp |
| Bayer Healthcare Pharmaceuticals INC. | $355.00 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $270.58 | 2020-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $232.23 | 2019-2025 | Jynarque |
| Glaxosmithkline, LLC. | $225.88 | 2022-2025 | Benlysta, Shingrix, Arexvy |
| Calliditas Therapeutics US INC. | $192.97 | 2022-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.22 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $146.47 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $139.31 | 2024-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $105.81 | 2022-2024 | Lupkynis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $61.11 | 2025 | Rybelsus, Ozempic |
| Genentech USA, INC. | $54.10 | 2024-2025 | Itovebi, Phesgo, Gazyva |
| Horizon Therapeutics Plc | $52.39 | 2019-2023 | Krystexxa |
| Travere Therapeutics, INC. | $52.17 | 2022-2023 | |
| Fresenius USA Marketing, INC. | $49.37 | 2022-2024 | Velphoro |
| Daiichi Sankyo INC. | $43.80 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $30.94 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.47 | 2023 | Xarelto |
| Mallinckrodt Enterprises LLC | $18.46 | 2019 | |
| Shield Therapeutics INC | $14.86 | 2025 | |
| Pfizer INC. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.